You have no items in your cart.
Molecule Safely Eases Dyskinesia Tied to Levodopa in Primate Model

A newly discovered oral molecule, called PD13R, significantly lessened levodopa-induced dyskinesia, its involuntary and jerky movements, while maintaining the therapy’s benefits in a non-human primate model of Parkinson’s disease. Notably, in contrast to Gocovri (amantadine) — an approved therapy to treat levodopa-induced dyskinesia — PD13R did not affect the animals’ sleep, suggesting this new molecule may be a safer as well as effective in treating dyskinesia, the researchers noted. “We were very excited to see the robust…